ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "treatment"

  • Abstract Number: 080 • 2020 Pediatric Rheumatology Symposium

    Therapeutic Interferon Gamma Neutralization with Emapalumab in Patients with NRLC4- and CDC42-Associated Diseases Characterized by Recurrent and Severe Hemophagocytic Lymphohistiocytosis

    Claudia Bracaglia1, Antonella Insalaco 1, Giulia Marucci 1, Manuela Pardeo 1, Emanuela Sacco 1, Virginia Messia 1, Giusi Prencipe 1, Ivan Caiello 1, Sarka Fingerhutova 2, Pavla Dolezalova 2, Veronica Asnaghi 3, Maria Ballabio 3, Cristina de Min 3 and Fabrizio De Benedetti 1, 1Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, 2Paediatric Rheumatology and Autoinflammatory Diseases Unit, General University Hospital, Prague, Czech Republic, 3Swedish Orphan Biovitrum AG (Sobi), Basel, Switzerland

    Background/Purpose: Interferon gamma (IFNγ) is a pivotal mediator of HLH. Emapalumab (a fully human anti-IFNγ monoclonal antibody) is efficacious in patients with primary HLH. In…
  • Abstract Number: 093 • 2020 Pediatric Rheumatology Symposium

    Treatment of Systemic Juvenile Idiopathic Arthritis in the CARRA Registry

    Ginger Janow 1, Timothy Beukelman 2, Yukiko Kimura 3, Rayfel Schneider 4, Shalini Mohan 5, Gail Rodich 6 and Mary Beth Son7 for the CARRA investigators, 1Joseph M. Sanzari Children's Hospital at Hackensack Meridian Health, Hackensack, New Jersey, 2University of Alabama at Birmingham, Birmingham, 3Hackensack Meridian School of Medicine, Hackensack, 4The Hospital for Sick Children, Toronto, Canada, 5Genentech, Inc., South San Francisco, 6Genentech, Mill Valley, 7Boston Children's Hospital, Boston, Massachusetts

    Background/Purpose: The treatment of systemic juvenile idiopathic arthritis (SJIA) has changed dramatically over the past decade, associated with overall improvement in functional outcomes.  There may…
  • Abstract Number: 098 • 2020 Pediatric Rheumatology Symposium

    Early Treatment with Anakinra in Systemic Juvenile Idiopathic Arthritis

    Manuela Pardeo1, Claudia Bracaglia 1, Emanuela Sacco 1, Denise Pires Marafon 1, Antonella Insalaco 1, Giulia Marucci 1, Rebecca Nicolai 2, Virginia Messia 1 and Fabrizio De Benedetti 1, 1Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, 2IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy

    Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) should be considered as a polygenic autoinflammatory disease. Interleukin 1 (IL-1) has been shown to be a major mediator…
  • Abstract Number: 003 • 2020 Pediatric Rheumatology Symposium

    Implementing Treat to Target Approach in the Care of Juvenile Idiopathic Arthritis Across a Network of Pediatric Rheumatology Centers

    Julia Harris1, Esi Morgan 2, Janalee Taylor 2, Tingting Qiu 3, Nancy Griffin 3, Anne Paul 4, C. April Bingham 5, Danielle Bullock 6, Kerry Ferraro 7, Mileka Gilbert 8, Y. Ingrid Goh 9, Olha Halyabar 10, Karla Jones 11, Melanie Kohlheim 12, Daniel J. Lovell 13, Emily Smitherman 14, Anjie Vago 7, Jennifer Weiss 15, Cagri Yildirim-Toruner 11, Angela Young 7, Michelle Batthish 16, Beth Gottlieb 17, Melissa Hazen 18, Ronald Laxer 19, Tzielan Lee 20, Melissa Mannion 14, Judyann Olson 21, Michael Shishov 22, Salma Siddique 23, Charles Spencer 24, Mary Toth 25, Sheetal Vora 26 and Jon Burnham 27, 1Children's Mercy Kansas City, Overland Park, 2Cincinnati Children's Hospital, Cincinnati, 3Cincinnati Children's Hospital Medical Center, Cincinnati, 4Cincinnati Children's Hospital Medical Centre, Cincinnati, 5Penn State Children's Hospital, Allentown, 6University of Minnesota, Minneapolis, 7Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, 8Medical University of South Carolina, Charleston, South Carolina, 9The Hospital for Sick Children, Toronto, Canada, 10Children's Hospital/Boston Medical Center, Boston, 11Nationwide Children's Hospital, Columbus, 12, 13Cincinnati, 14University of Alabama at Birmingham, Birmingham, 15Hackensack University Medical Center, Hackensack, 16McMaster University, Hamilton, Canada, 17Cohen Children's Medical Center, Lake Success, 18Boston, 19The Hospital for Sick Children and University of Toronto, Toronto, Canada, 20Stanford Children's, Palo Alto, 21Medical College of Wisconsin: Children's Wisconsin, Wauwatosa, Wisconsin, 22Phoenix Children's Hospital, Phoenix, 23Nemours/A.I.duPont Hospital for Children, Wilmington, 24Jackson, 25Nemours Foundation, Orlando, 26Atrium Health Levine Children's Hospital, Charlotte, 27Children's Hospital of Philadelphia, Philadelphia

    Background/Purpose: In 2018, an international task force published a recommended Treat to Target (T2T) approach to JIA treatment. This treatment paradigm involves setting a treatment…
  • Abstract Number: 024 • 2020 Pediatric Rheumatology Symposium

    Abatacept Treatment Reduces Cutaneous and Joint Activity in Juvenile Localized Scleroderma

    Suzanne Li1, Sarah Ishaq 2, Mary Buckley 3, Kathryn Torok 4, Barbara Edelheit 5, Kaleo Ede 6 and C. Egla Rabinovich 7, 1Joseph M. Sanzari Children's Hospital Hackensack Meridian Health, Hackensack, 2Montclair State University, montclair, 3Duke University, Durham, 4Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, 5CT Children's Medical Center, Hartford, 6Phoenix Children's Hospital, Phoenix, 7Duke University Hospital, Durham

    Background/Purpose: Juvenile localized scleroderma (jLS) is an autoimmune disease commonly associated with damage. Damage includes dyspigmentation, tissue atrophy, arthropathy, hemiatrophy, vision loss, and seizures. To…
  • Abstract Number: 038 • 2020 Pediatric Rheumatology Symposium

    Change in Treatments and Outcomes After Implementation of a National Diagnosis and Treatment Guarantee Program for Juvenile Idiopathic Arthritis in Chile

    Sara Concha1, Pamela Morales 2, Eduardo Talesnik 1 and Arturo Borzutzky 1, 1Department of Infectious Diseases and Pediatric Immunology, School of Medicine, Pontificia Universidad Católica de Chile., Santiago, Chile, 2Department of Pediatric, Clinica Las Condes, Santiago, Chile

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is currently the most common childhood chronic rheumatic disease with high burden and socioeconomic costs for the patient’s family and…
  • Abstract Number: 060 • 2020 Pediatric Rheumatology Symposium

    Parsing Apart the Pain Experience: Exploring Treatment-Related Pain in Juvenile Idiopathic Arthritis

    Yvonne Brandelli1, Christine Chambers 2, Perri Tutelman 1, Jennifer Stinson 3, Adam Huber 4 and Jennifer Wilson 5, 1Dalhousie University, Halifax, Nova Scotia, Canada, 2Dalhousie University & IWK Health Centre, Halifax, Nova Scotia, Canada, 3University of Toronto & The Hospital for Sick Children, Toronto, Ontario, Canada, 4IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, 5Cassie and Friends, Vancouver, British Columbia, Canada

    Background/Purpose: Pain is one of the most frequently reported symptoms among children with Juvenile Idiopathic Arthritis (JIA), and in recent decades our understanding and assessment…
  • Abstract Number: L11 • 2019 ACR/ARP Annual Meeting

    Maintenance of Remission Following Dose De-Escalation of Abatacept in Early, MTX-Naïve, ACPA-Positive Patients with RA: Results from a Randomized Phase IIIb Study

    Paul Emery1, Yoshiya Tanaka 2, Vivian Bykerk 3, Thomas W.J. Huizinga 4, Gustavo Citera 5, Clifton Bingham 6, Subhashis Banerjee 7, Benjamin Soule 8, Marleen Nys 9, Sean Connolly 10, Robert Wong 10, Kuan-Hsiang Gary Huang 7 and Roy Fleischmann 11, 1University of Leeds and Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, 2University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 3Hospital for Special Surgery, New York City, 4Leiden University Medical Center, Leiden, Netherlands, 5Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, 6Johns Hopkins University, Baltimore, 7Bristol-Myers Squibb, Princeton, NJ, 8Bristol-Myers Squibb, Princeton, New Jersey, 9Bristol-Myers Squibb, Braine L'Alleud, Belgium, 10Bristol-Myers Squibb, Princeton, 11Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: Although EULAR/ACR guidelines suggest tapering biologics following sustained remission in patients (pts) with RA, specific de-escalation (DE) regimens are not fully defined. The Phase…
  • Abstract Number: L13 • 2019 ACR/ARP Annual Meeting

    Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Biologic-naïve Patients with Active Psoriatic Arthritis: Week 24 Results of the Phase 3, Randomized, Double-blind, Placebo-controlled Study

    Philip J. Mease1, Proton Rahman 2, Alice B. Gottlieb 3, Elizabeth Hsia 4, Alexa Kollmeier 5, Xie Xu 6, Ramanand Subramanian 5, Prasheen Agarwal 5, Shihong Sheng 5, Bei Zhou 5, Désirée van der Heijde 7 and Iain McInnes 8, 1Swedish Medical Center and University of Washington, Seattle, Washington, 2Memorial University of Newfoundland, Newfoundland, Canada, 3Icahn School of Medicine at Mt Sinai, NY, NY, New York, New York, 4Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, Pennsylvania, 5Janssen Research & Development, LLC, Spring House, Pennsylvania, 6Janssen Research & Development, LLC, Spring House, 7Leiden University Medical Center, Leiden, Netherlands, 8Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Guselkumab (GUS), an anti-interleukin-23p19 monoclonal antibody, is approved for psoriasis (PsO). We assessed GUS efficacy and safety in DISCOVER-1 (ACR2019 Abstract ID697955) and DISCOVER-2,…
  • Abstract Number: L17 • 2019 ACR/ARP Annual Meeting

    Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized Controlled Trial

    Eric Morand1, Richard Furie 2, Yoshiya Tanaka 3, Ian Bruce 4, Anca Askanase 5, Christophe Richez 6, Sang-Cheol Bae 7, Philip Brohawn 8, Lilia Pineda 9, Anna Berglind 10 and Raj Tummala 9, 1Monash University, Melbourne, Victoria, Australia, 2Zucker School of Medicine at Hofstra/Northwell, New York, 3University of Occupational and Environmental Health, Kitakyushu, Japan, 4University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, 5Columbia University, New York, 6CHU de Bordeaux-GH Pellegrin, Bordeaux, France, 7Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 8Former employee of AstraZeneca, Gaithersburg, Maryland, 9AstraZeneca, Gaithersburg, Maryland, 10AstraZeneca, Gothenburg, Sweden

    Background/Purpose: Anifrolumab, a human monoclonal antibody to the type I IFN receptor subunit 1, had robust efficacy in a phase 2 study in patients with…
  • Abstract Number: 513 • 2019 ACR/ARP Annual Meeting

    Upadacitinib as Monotherapy in Patients with Rheumatoid Arthritis: Results at 48 Weeks

    Josef Smolen1, Paul Emery 2, William Rigby 3, Yoshiya Tanaka 4, Juan Ignacio Vargas 5, Nemanja Damjanov 6, Manish Jain 7, Yunxia Sui 8, Jose Jeffrey Enejosa 9, Aileen Pangan 10, Heidi Camp 9 and Stanley Cohen 11, 1Medical University of Vienna, Vienna, Austria, 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, 3Dartmouth-Hitchcock Medical Center, Lebanon, 4University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 5Quantum Research, Puerto Varas, Chile, 6Institute of Rheumatology, Belgrade University School of Medicine, Belgrade, Serbia, Belgrade, Serbia, 7Rheumatology, Great Lakes Clinical Trials, Great Lakes, 8AbbVie Inc., Chicago, 9AbbVie Inc., North Chicago, IL, 10AbbVie Inc., North Chicago, 11Metroplex Clinical Research Center, Dallas, TX

    Background/Purpose: In the SELECT-MONOTHERAPY trial, upadacitinib (UPA), an oral JAK1-selective inhibitor, showed efficacy when used as monotherapy over 14 weeks (wks) in rheumatoid arthritis (RA)…
  • Abstract Number: 848 • 2019 ACR/ARP Annual Meeting

    Risk of Serious Infection with Long-Term Use of Low-Dose Glucocorticoids in Patients with Rheumatoid Arthritis

    Michael George1, Joshua Baker 2, Kevin Winthrop 3, Qufei Wu 2, Lang Chen 4, Fenglong Xie 5, Huifeng Yun 4 and Jeffrey Curtis 4, 1University of Pennsylvania, Philadelphia, 2University of Pennsylvania, Philadelphia, PA, 3Oregon Health and Science University, Portland, OR, 4University of Alabama at Birmingham, Birmingham, AL, 5University of Alabama at Birmingham, Birmingham

    Background/Purpose: As many as 30-40% of patients with RA remain on long term glucocorticoids. Infection risk with higher dose glucocorticoids is well known, but evidence…
  • Abstract Number: 1429 • 2019 ACR/ARP Annual Meeting

    Results at 6 Months of Abatacept vs TNF-α Blockers in Patients with Severe, Long-standing, DMARDs Resistant Rheumatoid Arthritis

    Omar Valenzuela 1, Sebastian Ibanez2, Maria Paz Poblete 3, Claudia Mardones 2, Francisco Silva 2, Maria Jose Villar 2 and Katherine Mogollones 1, 1Facultad de Medicina Clinica Alemana -UDD, Santiago, Region Metropolitana, Chile, 2Facultad de Medicina Clinica Alemana - UDD, Santiago, Region Metropolitana, Chile, 3Rheumatology dpt., Facultad de Medicina Clinica Alemana - UDD, Santiago, Region Metropolitana, Chile

    Background/Purpose: Since January 2016, Chilean patients with rheumatoid arthritis (RA), with severe activity despite the use of 3 DMARDs for at least 6 months, have guaranteed access…
  • Abstract Number: 2381 • 2019 ACR/ARP Annual Meeting

    Baseline Characteristics Associated with Sustained SDAI Remission Following Treatment with Abatacept in Combination with MTX Compared with Abatacept Placebo in Combination with MTX in ACPA Positive Patients with Early RA

    Paul Emery1, Yoshiya Tanaka 2, Vivian Bykerk 3, Clifton Bingham 4, Thomas Huizinga 5, Gustavo Citera 6, Kuan-Hsiang Gary Huang 7, Sean Connolly 7, Yedid Elbez 8, Karissa Lozenski 9 and Roy Fleischmann 10, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, 2University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 3Hospital for Special Surgery, New York City, NY, 4Johns Hopkins University, Baltimore, MD, 5Leiden University Medical Center, Leiden, Netherlands, 6Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, 7Bristol-Myers Squibb, Princeton, NJ, 8Excelya, Boulogne-Billancourt, France, 9Bristol-Myers Squibb, Princeton, 10Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: The Phase IIIb Assessing Very Early Rheumatoid arthritis Treatment (AVERT)-2 trial (NCT02504268) is evaluating SC abatacept (ABA) + MTX versus ABA placebo (PBO) +…
  • Abstract Number: 515 • 2019 ACR/ARP Annual Meeting

    Clinical Responses in Patients with Inadequate Response to bDMARDs upon Treatment with Upadacitinib

    Michael Weinblatt1, Glen Thomson 2, Kun Chen 3, Sebastian Meerwein 4, Casey Schlacher 5 and John Cush 6, 1Brigham and Women's Hospital, Boston, MA, USA, Boston, MA, 2CIADS Research, Winnipeg, Canada, 3AbbVie Inc., North Chicago, 4AbbVie GmbH Co. KG, Ludwigshafen, Germany, Wiesbaden, Germany, 5AbbVie Inc., North Chicago, IL, 65Baylor University Medical Center, Dallas

    Background/Purpose: Upadacitinib (UPA), a JAK1-selective inhibitor, demonstrated efficacy in the SELECT-BEYOND study in patients (pts) with moderate to severe rheumatoid arthritis (RA) on a stable…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 22
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology